Scarica l'app Stockscreener
14.88
0.80%
-0.12
Dopo l'orario di chiusura:
14.80
-0.08
-0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.00
Aprire:
$14.8
Volume 24 ore:
1.65M
Relative Volume:
1.16
Capitalizzazione di mercato:
$1.91B
Reddito:
$298.30M
Utile/perdita netta:
$298.21M
Rapporto P/E:
6.8771
EPS:
2.1637
Flusso di cassa netto:
$166.93M
1 W Prestazione:
-3.06%
1M Prestazione:
-12.32%
6M Prestazione:
+2.41%
1 anno Prestazione:
+60.95%
Intervallo 1D:
$14.36
$15.25
Intervallo di 1 settimana:
$14.36
$15.77
Portata 52W:
$9.33
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
14.88 | 1.96B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Strong Growth Potential with an 11.7% Upside - DirectorsTalk Interviews
AUPH|Aurinia Pharmaceuticals Inc|Price:15.215|Chg%:-0.135 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Balance Sheet - TradingKey
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc. Revenue Breakdown – LS:A1W7D4 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.350|Chg%:+0.110 - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Cash Flow - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AUPH Q2'26 Earnings: revenue estimate is 80.45M USD - TradingView
Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data - Stocktwits
Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Proxy filing Summary - Quartr
Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary - Quartr
Aurinia Pharmaceuticals (AUPH) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Aurinia Pharmaceuticals (AUPH) Q4 2024 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Q4 2025 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Investors - Aurinia Pharmaceuticals Inc.
bullish divergence on the hourly has held above support at 15.50, i like the stock 😀 - Moomoo
Price to earnings forward of Aurinia Pharmaceuticals Inc. – SWB:IKAP - TradingView
Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy? - Sahm
Price to earnings forward of Aurinia Pharmaceuticals Inc. – MUN:IKAP - TradingView
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca
Aurinia launches trial combining lupus nephritis treatments - Investing.com
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo
Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - Ad-hoc-news.de
Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
AUPHAurinia Pharmaceuticals Inc Latest SEC Filings - Finviz
Document - SEC.gov
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why - Yahoo Finance
If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo
Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey
IKAP Forecast — Price Target — Prediction for 2027 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Aurinia Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:AUPH) - TradingView
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):